drugset / Trial / NCT00332046

fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder

NCT00332046

Phase 1 Completed 57 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindDiagnostic

Summary

Evidence suggests the use of neuroimaging to detect therapeutic effects of anxiolytic treatment when appropriate cognitive-emotional tasks are use to activate the emotional brain neurocircuitry believed to be involved in the core symptoms of the disease.

Timeline

Start
2006-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Casopitant Small molecule

Indications